![](https://imgproxy.divecdn.com/hyrpDVpzL7aV5JSIJy54iZLYyql_6nipdk1JbE0H5rE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODIwMTg1MzY0LmpwZw==.webp)
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of neuroendocrine tumor.
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of neuroendocrine tumor.
© 2023 LBNN - All rights reserved.